Vaccitech Ltd.

https://www.vaccitech.co.uk

Vaccitech is a late-stage T cell immunotherapy company developing non-replicating viral vectors as vaccines to treat and prevent cancer and infectious diseases. The company’s proprietary technology platform, comprising Chimp Adenovirus Oxford (prime) and MVA (boost), is able to create high magnitude CD8+ and CD4+ T cell responses, which can be utilized to clear foreign pathogens and tumours. The Vaccitech prime-boost platform is licenced from the prestigious Jenner Institute for vaccine research at the University of Oxford. This platform has generated a robust pipeline of eight programmes (four of which are funded through partners). Vaccitech currently has a Phase 2b clinical programme for influenza and is poised to enter the clinic with HBV and HPV therapeutics. Vaccitech is also progressing other products funded by partners, including a Phase 2a study in prostate cancer and Phase 1 for MERS. Vaccitech is backed by leading investment institutions, including GV (formerly Google Ventures), Sequoia China and Oxford Sciences Innovation. *

	Start	2016-05-01 established (s-off)
	End	2021-03-31 reorganised
	Group	Vaccitech (Group)
	Predecessor	University of Oxford, Jenner Institute
	Industry	vaccine technology
	Industry 2	T cell therapy
	Person	Enright, Bill (Vaccitech 201908– CEO before Altimmune + GenVec + Biotech Venture Management + Life Technologies)
	Person 2	Evans, Thomas G. (Tom) (Vaccitech 201908– CSO before CEO before Vical + Novartis + Aeras)

	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Street	Heatley Road Oxford Science Park, Schrodinger Building
	City	OX4 4GE Oxford, Oxfordshire
	Tel	+44-1865-818808
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Vaccitech Ltd.. (8/27/19). "Press Release: Vaccitech Appoints Bill Enright as New Chief Executive Officer". Philadeliphia, PA & Oxfordshire.

		Record changed: 2023-07-10